Biophytis has signed a New Convertible Bond Financing of €24 million from Atlas to Continue the Development of Sarconeos (BIO101). Read the Press Release
Biophytis today announces that it has received approval from Brazil’s National Health Surveillance Agency (ANVISA) to begin the Phase 2 OBA clinical trial for obesity in Brazil and shares the…
Biophytis provides an update on the rollout of its joint venture in Hong Kong (see details in the “About” section below) and shares its short- and medium-term outlook. Landmark milestones…
Biophytis announces the publication of its parent company financial statements for the fiscal year ended December 31, 2025, prepared in accordance with French accounting rules and principles and approved by…
Biophytis reports its provisional, unaudited financial results for the fiscal year 2025 and provides an update on its strategic outlook.
Biophytis announces the temporary suspension of trading in its shares on Euronext. This suspension follows the failure to publish the annual financial report for the fiscal year ended December 31,…
Biophytis today announced the submission of the registration filing for its joint venture in Hong Kong with its Asian partners, including Ronghui Renhe Life Technology, a leading Chinese conglomerate primarily…
